MCID: CRV043
MIFTS: 43

Cervical Dystonia

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Cervical Dystonia

MalaCards integrated aliases for Cervical Dystonia:

Name: Cervical Dystonia 12 50 14
Spasmodic Torticollis 12 50

Classifications:



External Ids:

Disease Ontology 12 DOID:0050840
ICD10 33 G24.3

Summaries for Cervical Dystonia

NIH Rare Diseases : 50 cervical dystoniais a neurological condition characterized by excessive pulling of the muscles of the neck and shoulder resulting in abnormal movements of the head (dystonia). most commonly, the head turns to one side or the other. tilting sideways, or to the back or front may also occur. the turning or tilting movements may be accompanied by shaking movement (tremor) and/or soreness of the muscles of the neck and shoulders. cervical dystonia can occur at any age, but most cases occur in middle age. it often begins slowly and usually reaches a plateau over a few months or years. the cause of cervical dystonia is often unknown. in some cases there is a family history. several genes have been associated with cervical dystonia, including gnal, thap1, ciz1, and ano3. other cases may be linked to an underlying disease (e.g. parkinson disease), neck trauma, or certain medications. treatment may include local injections of botulinum toxin, pain medications, benzodiazepines (anti-anxiety medications), anticholinergics, physical therapy, or surgery. last updated: 11/30/2016

MalaCards based summary : Cervical Dystonia, also known as spasmodic torticollis, is related to dystonia 23 and leukoencephalopathy with dystonia and motor neuropathy. An important gene associated with Cervical Dystonia is CIZ1 (CDKN1A Interacting Zinc Finger Protein 1), and among its related pathways/superpathways are TCR Signaling (Qiagen) and HTLV-I infection. The drugs Acetylcholine and Menthol have been mentioned in the context of this disorder. Affiliated tissues include brain, cerebellum and testes.

Disease Ontology : 12 A focal dystonia that is characterized by simultaneous contraction of the agonist and antagonist muscles that control the position of the head contracting during dystonic movement which causes the neck to involuntarily turn to the left, right, upwards, and/or downwards.

Wikipedia : 72 Spasmodic torticollis is an extremely painful chronic neurological movement disorder causing the neck to... more...

Related Diseases for Cervical Dystonia

Diseases related to Cervical Dystonia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 111)
id Related Disease Score Top Affiliating Genes
1 dystonia 23 11.4
2 leukoencephalopathy with dystonia and motor neuropathy 11.2
3 meige syndrome 11.2
4 torticollis, familial 11.1
5 dystonia-11, myoclonic 11.1
6 dystonia 11.0
7 cervicitis 11.0
8 x-linked dystonia-parkinsonism/lubag 11.0
9 dystonia 24 10.9
10 dystonia 4, torsion, autosomal dominant 10.8
11 torsion dystonia 7 10.8
12 torsion dystonia 4 10.8
13 adolescent-onset dystonia of mixed type 10.8
14 osteogenesis imperfecta congenita, microcephaly, and cataracts 10.5 HLA-DQA1 HLA-DQB1
15 pedophilia 10.5 HLA-DQA1 HLA-DQB1
16 fruit allergy 10.4 HLA-DQB1 HLA-DRB1
17 hypereosinophilic syndrome 10.4 HLA-DQA1 HLA-DRB1
18 light chain deposition disease 10.4 HLA-DQB1 HLA-DRB1
19 juvenile sialidosis type 2 10.4 HLA-DQB1 HLA-DRB1
20 idiopathic subglottic tracheal stenosis 10.4 HLA-DQB1 HLA-DRB1
21 reese retinal dysplasia 10.4 HLA-DQB1 HLA-DRB1
22 mosaic trisomy 1 10.4 HLA-DQB1 HLA-DRB1
23 autoimmune retinopathy 10.4 HLA-DQB1 HLA-DRB1
24 progressive myoclonus epilepsy 10.4 HLA-DQB1 HLA-DRB1
25 limb-body wall complex 10.4 HLA-DQB1 HLA-DRB1
26 kernicterus due to isoimmunization 10.4 HLA-DQA1 HLA-DRB1
27 transient retinal arterial occlusion 10.4 HLA-DQB1 HLA-DRB1
28 pellagra like syndrome 10.4 HLA-DQB1 HLA-DRB1
29 clear cell adenocarcinoma of ovary 10.4 HLA-DQB1 HLA-DRB1
30 ampulla of vater neoplasm 10.4 HLA-DQA1 HLA-DQB1
31 acanthoma 10.4 HLA-DQA1 HLA-DRB1
32 lymphocytic colitis 10.4 HLA-DQB1 HLA-DRB1
33 papillary squamous carcinoma 10.3 HLA-DQB1 HLA-DRB1
34 blepharospasm 10.3
35 reproductive system disease 10.3 HLA-DQB1 HLA-DRB1
36 b cell linker protein deficiency 10.3 HLA-DQB1 TOR1A
37 cryptococcosis 10.3 HLA-DQB1 HLA-DRB1
38 infantile hypotonia 10.3 HLA-DQB1 HLA-DRB1
39 intestinal impaction 10.3 BDNF CAMP
40 anismus 10.3 CAMP TOR1A
41 anaerobic meningitis 10.2 HLA-DQB1 HLA-DRB1
42 tremor 10.2
43 histrionic personality disorder 10.2 BDNF CAMP
44 moderately severe hemophilia b 10.2 HLA-DQB1 HLA-DRB1
45 myopathy, distal, with early respiratory failure, autosomal dominant 10.1 HLA-DQB1 TOR1A
46 breast hemangiopericytoma 10.1 HLA-DQA1 HLA-DQB1 HLA-DRB1
47 biemond syndrome 10.1 HLA-DQA1 HLA-DQB1 HLA-DRB1
48 specific developmental disorder 10.1 HLA-DQA1 TOR1A
49 subcorneal pustular dermatosis 10.1 HLA-DQA1 HLA-DQB1
50 ovarian surface papilloma 10.1 HLA-DQA1 HLA-DQB1 HLA-DRB1

Graphical network of the top 20 diseases related to Cervical Dystonia:



Diseases related to Cervical Dystonia

Symptoms & Phenotypes for Cervical Dystonia

Drugs & Therapeutics for Cervical Dystonia

Drugs for Cervical Dystonia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-84-3 187
2
Menthol Approved Phase 4 2216-51-5 16666
3 abobotulinumtoxinA Phase 4,Phase 3,Phase 1,Phase 2
4 Botulinum Toxins Phase 4,Phase 3,Phase 2,Phase 1
5 Botulinum Toxins, Type A Phase 4,Phase 3,Phase 1,Phase 2
6 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Neuromuscular Agents Phase 4,Phase 3,Phase 1,Phase 2
8 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
9 onabotulinumtoxinA Phase 4,Phase 3,Phase 1,Phase 2
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
12 rimabotulinumtoxinB Phase 4,Phase 2
13 incobotulinumtoxinA Phase 4,Phase 3,Phase 2
14
Dronabinol Approved, Illicit Phase 2 1972-08-3 16078 2978
15
Etanercept Approved, Investigational Phase 1, Phase 2 185243-69-0
16
Amlodipine Approved Phase 2 88150-42-9 2162
17 Etiracetam Investigational Phase 2 33996-58-6
18 Analgesics Phase 2,Phase 1
19 Analgesics, Non-Narcotic Phase 2,Phase 1
20 Cannabinoid Receptor Agonists Phase 2
21 Hallucinogens Phase 2
22 Hormone Antagonists Phase 2
23 Hormones Phase 2
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
25 Psychotropic Drugs Phase 2
26 Anti-Inflammatory Agents Phase 1, Phase 2
27 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
28 Antirheumatic Agents Phase 1, Phase 2
29 Autoantibodies Phase 1, Phase 2
30 Gastrointestinal Agents Phase 1, Phase 2
31 Immunosuppressive Agents Phase 1, Phase 2
32 Antihypertensive Agents Phase 2
33 calcium channel blockers Phase 2
34 Calcium, Dietary Phase 2
35 Vasodilator Agents Phase 2
36 Anticonvulsants Phase 2
37 Nootropic Agents Phase 2
38
Flumazenil Approved 78755-81-4 3373
39
Cortisone acetate Approved 1950-04-4, 50-04-4 5745
40
Methylprednisolone Approved, Vet_approved 83-43-2 6741
41
Prednisolone Approved, Vet_approved 50-24-8 5755
42
Trihexyphenidyl Approved 58947-95-8, 144-11-6 5572
43 Dihydroxyphenylalanine
44
Cortisone 53-06-5 222786
45 Methylprednisolone acetate
46 Methylprednisolone Hemisuccinate
47 Prednisolone acetate
48 Prednisolone hemisuccinate
49 Prednisolone phosphate
50 Antiparkinson Agents

Interventional clinical trials:

(show top 50) (show all 104)

id Name Status NCT ID Phase Drugs
1 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
2 Botox for Cervical Dystonia Following EMG Mapping Completed NCT00773253 Phase 4 Botulinum toxin A
3 An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia Completed NCT00702754 Phase 4
4 A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia Completed NCT00950664 Phase 4 Dysport® (abobotulinumtoxinA);Botox® (onabotulinumtoxinA)
5 Open-Label Non-Inferiority Study Evaluating the Efficacy and Safety of Xeomin® in Subjects With Cervical Dystonia Flex Completed NCT01486264 Phase 4
6 Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia Completed NCT00541905 Phase 4 NT 201
7 Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
8 A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm Completed NCT02245958 Phase 4
9 Neurotoxin and Physical Therapy Completed NCT02177617 Phase 4 Botox injection
10 Effect of Botulinum Toxin Type A on Swallowing in Patients With Cervical Dystonia Completed NCT01384214 Phase 4
11 Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia Completed NCT00528541 Phase 4
12 Post Marketing Surveillance Study of Dysport Completed NCT00210431 Phase 4
13 OnabotulinumtoxinA in the Management of Psychogenic Dystonia Recruiting NCT02618889 Phase 4
14 Frontalis Botulinum Toxin Not yet recruiting NCT03186001 Phase 4 Abobotulinum toxin A
15 Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia Terminated NCT00432341 Phase 4
16 Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia Completed NCT00447772 Phase 3 Botulinum type A toxin (Dysport®)
17 Double-Blind, Multicenter Study to Assess the Efficacy of Bilateral Pallidal Stimulation in Patients With Medically Refractory Primary Cervical Dystonia Completed NCT00148889 Phase 3
18 Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia. Completed NCT01753310 Phase 3 Dysport®;Placebo
19 Study Comparing Short Term Efficacy of Dysport® and Dysport RU® to Placebo, and to Assess Efficacy and Safety of Dysport RU® of Subjects With Cervical Dystonia Completed NCT01261611 Phase 3 Botulinum type A toxin (Dysport RU®);Botulinum type A toxin (Dysport®);Placebo
20 Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia Completed NCT00288509 Phase 3 abobotulinumtoxinA (Dysport) 250-1000 units
21 Randomized, Placebo-Controlled Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia Completed NCT00257660 Phase 3 Botulinum type A toxin (Dysport®);Placebo
22 Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia Completed NCT01753336 Phase 3 Dysport®
23 IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia Completed NCT00407030 Phase 3 incobotulinumtoxinA (Xeomin) (240 Units);incobotulinumtoxinA (Xeomin) (120 Units);Placebo
24 Meditoxin® Treatment in Patients With Cervical Dystonia Recruiting NCT03232320 Phase 3 Meditoxin;Placebo
25 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor Recruiting NCT02555982 Phase 3 BOTOX ® 200 Unités;Placebo
26 Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia Active, not recruiting NCT02604186 Phase 2, Phase 3
27 Efficacy of Dronabinol for the Treatment of Cervical Dystonia Unknown status NCT00418925 Phase 2 Dronabinol
28 ASIS for Botox in Cervical Dystonia Unknown status NCT02074293 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Botox intramuscularly at Week 6;Efficacy of Botox intramuscularly at Week 12;Efficacy of Botox intramuscularly at Week 18;Efficacy of Botox intramuscularly at Week 24;Efficacy of Botox intramuscularly at Week 30;Efficacy of Botox subdermally at Week 6;Efficacy of Botox subdermally at Week 12;Efficacy of Botox subdermally at Week 18;Efficacy of Botox subdermally at Week 24;Efficacy of Botox subdermally at Week 30;Adverse Reactions of Botox intramuscularly;Adverse Reactions of Botox subdermally
29 Safety and Tolerability of Perampanel in Cervical Dystonia Unknown status NCT02131467 Phase 1, Phase 2 Perampanel
30 ASIS for Enbrel in Plaque Psoriasis Unknown status NCT02112097 Phase 1, Phase 2 Gadolinium;Gadolinium;Gadolinium;Efficacy of Enbrel subcutaneously at Week 12;Efficacy of Enbrel subcutaneously at Week 24;Efficacy of Enbrel subcutaneously at Week 36;Efficacy of Enbrel subdermally at Week 12;Efficacy of Enbrel subdermally at Week 24;Efficacy of Enbrel subdermally at Week 36;PASI 75 n(%) subcutaneously at Week 12;PASI 75 n(%) subcutaneously at Week 24;PASI 75 n(%) subcutaneously at Week 36;PASI 75 n(%) subdermally at Week 12;PASI 75 n(%) subdermally at Week 24;PASI 75 n(%) subdermally at Week 36;Adverse Reactions of Enbrel subcutaneously;Adverse Reactions of Enbrel subdermally at Week 36;Gadolinium;Gadolinium;Gadolinium
31 Botulinum Toxin Type A (Botox) for the Treatment of Cervical Dystonia and Upper Thoracic Muscular Pain Completed NCT00178945 Phase 1, Phase 2 Botulinum Toxin Type A
32 Study to Evaluate Safety, Efficacy of Botulinum Toxin Type A in Patients With Cervical Dystonia Completed NCT00564681 Phase 2 Normal Saline
33 Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Dose-Response, Study of E2014 in Patients WIth Spasmodic Torticollis Completed NCT00165776 Phase 2 BOTULINUM TOXIN TYPE B
34 Study for Determine the Safety and Efficacy of Clostridium Botulinum Toxin Type A in Subjects With Cervical Dystonia Completed NCT01588574 Phase 2
35 Amlodipine Plus Botulinum Toxin for Focal Dystonia Completed NCT00015457 Phase 2 Amlodipine plus Botulinum toxin
36 Deep Brain Stimulation for Cervical Dystonia Completed NCT00105430 Phase 2
37 An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects Completed NCT00280384 Phase 2 E2014 (Botulinum toxin type B);E2014 (Botulinum toxin type B) Placebo
38 Deep Brain Stimulation in Patients With Dystonia Completed NCT00773604 Phase 1, Phase 2
39 Transcranial Electrical Polarization to Treat Focal Hand Dystonia Completed NCT00106782 Phase 2
40 Motor Training to Treat Hand Dystonia Completed NCT00021853 Phase 2
41 Clinical and Kinematic Assessment for Determination of Botox® Injection Parameters in Cervical Dystonia Recruiting NCT02662530 Phase 2 Botulinum Toxin Type A
42 Study of the Treatment of Tendinopathy Unruptured of Rotator Cuff by Intramuscular Injection of Botulinum Toxin Recruiting NCT02867787 Phase 2 Botox arm
43 Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia Active, not recruiting NCT02706795 Phase 2
44 Keppra for Cervical Dystonia Suspended NCT00760318 Phase 2 Keppra
45 Botulinum Toxin Injection Efficiency Unknown status NCT01041157 Phase 1
46 Deep Brain Stimulation to Treat Cervical Dystonia Completed NCT00132340 Phase 1
47 PurTox (Botulinum Toxin Type A) for the Treatment of Adult Onset Spasmodic Torticollis/Cervical Dystonia Completed NCT00549341 Phase 1 Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin
48 A Multicenter Pilot Study of Pallidal Deep Brain Stimulation for Cervical Dystonia Unknown status NCT00132990
49 Validation of the Implantation of a New Electrode for the Treatment of Dystonia Unknown status NCT02509338
50 Cerebellum and Cortical Plasticity: the Case of Dystonia Unknown status NCT01272154

Search NIH Clinical Center for Cervical Dystonia

Genetic Tests for Cervical Dystonia

Anatomical Context for Cervical Dystonia

MalaCards organs/tissues related to Cervical Dystonia:

39
Brain, Cerebellum, Testes, Globus Pallidus, Cortex, T Cells, Subthalamic Nucleus

Publications for Cervical Dystonia

Articles related to Cervical Dystonia:

(show top 50) (show all 620)
id Title Authors Year
1
Cervical sensorimotor control in idiopathic cervical dystonia: AA cross-sectional study. ( 28948067 )
2017
2
Functional activity of the sensorimotor cortex and cerebellum relates to cervical dystonia symptoms. ( 28594097 )
2017
3
Ixcellence NetworkAr: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection. ( 28676144 )
2017
4
Expanding the phenotype of phosphomannomutase-2 gene congenital disorder of glycosylation: Cervical dystonia. ( 28566178 )
2017
5
Interoceptive sensitivity in patients with cervical dystonia. ( 28827008 )
2017
6
Nonmotor symptoms in primary adult-onset cervical dystonia and blepharospasm. ( 28239516 )
2017
7
Evaluation of the Edrophonium Challenge Test for Cervical Dystonia. ( 28824069 )
2017
8
Endophenotyping in idiopathic adult onset cervical dystonia. ( 28511126 )
2017
9
The occurrence of lateral shift in cervical dystonia. ( 28054172 )
2017
10
Sensory tricks in primary blepharospasm and idiopathic cervical dystonia. ( 28488615 )
2017
11
Contributions of visual and motor signals in cervical dystonia. ( 27993890 )
2017
12
Cervical dystonia patients display subclinical gait changes. ( 28712731 )
2017
13
Spectral EMG Changes in Cervical Dystonia Patients and the Influence of Botulinum Toxin Treatment. ( 28832550 )
2017
14
Modulation of the muscle activity during sleep in cervical dystonia. ( 28525628 )
2017
15
Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia. ( 28478527 )
2017
16
Reply: Contributions of visual and motor signals in cervical dystonia. ( 27993889 )
2017
17
Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? ( 28888929 )
2017
18
Providing an imputation algorithm for missing values of longitudinal data using Cuckoo search algorithm: A case study on cervical dystonia. ( 28848643 )
2017
19
Measuring Disability in Patients With Cervical Dystonia According to the International Classification of Functioning, Disability and Health. ( 28621218 )
2017
20
Biased Visuospatial Attention in Cervical Dystonia. ( 28791940 )
2017
21
Adaptation of feedforward movement control is abnormal in patients with cervical dystonia and tremor. ( 28943258 )
2017
22
The Regions on the Light Chain of Botulinum Neurotoxin Type A Recognized by T Cells from Toxin-Treated Cervical Dystonia Patients. The Complete Human T-Cell Recognition Map of the Toxin Molecule. ( 28891721 )
2017
23
Ultrasound imaging and guidance in the management of cervical dystonia: A caveat on the compartmentalization of sternocleidomastoid muscle. ( 28851563 )
2017
24
Alterations of resting-state fMRI measurements in individuals with cervical dystonia. ( 28504361 )
2017
25
Brain Metabolic Changes of Cervical Dystonia with Spinocerebellar Ataxia Type 1 after Botulinum Toxin Therapy. ( 27432104 )
2016
26
A randomized trial of specialized versus standard neck physiotherapy in cervical dystonia. ( 26723272 )
2016
27
Poster 290 Efficacy and Safety of a 2 mL Dilution of AbobotulinumtoxinA Compared with Placebo in Adult Patients with Cervical Dystonia. ( 27673045 )
2016
28
Clinical and genetic features of cervical dystonia in a large multicenter cohort. ( 27123488 )
2016
29
Anatomy and cervical dystonia : "Dysfunction follows form". ( 27624726 )
2016
30
Overuse Cervical Dystonia: A Case Report and Literature Review. ( 27708983 )
2016
31
Striving for more good days: patient perspectives on botulinum toxin for the treatment of cervical dystonia. ( 27578965 )
2016
32
Botulinum toxin treatment failures in cervical dystonia: causes, management, and outcomes. ( 27113604 )
2016
33
Poster 498 Geographic Differences in the Characteristics of Cervical Dystonia Patients. ( 27673242 )
2016
34
British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin. ( 26976927 )
2016
35
Poster 296 AbobotulinumtoxinA Injection Patterns in Patients with Cervical Dystonia from the ANCHOR-CD Registry Study. ( 27673052 )
2016
36
Impact of Neu-botulinumtoxinA on the Severity and Quality of Life of Cervical Dystonia Patients. ( 27536464 )
2016
37
Neck Pain and Cervical Dystonia: Treatment Outcomes from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). ( 26910788 )
2016
38
A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. ( 26914922 )
2016
39
Electrophysiological interpretations of the clinical response to stimulation parameters of pallidal deep brain stimulation for cervical dystonia. ( 27562682 )
2016
40
The double-chin posture: Posterior sagittal shift in cervical dystonia. ( 27147170 )
2016
41
Deficient median nerve prepulse inhibition of the blink reflex in cervical dystonia. ( 27815976 )
2016
42
Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical Dystonia. ( 27021747 )
2016
43
Clinical and demographic characteristics related to onset site and spread of cervical dystonia. ( 27753188 )
2016
44
Botulinum toxin type B for cervical dystonia. ( 27176573 )
2016
45
Cervical dystonia: a neural integrator disorder. ( 27324878 )
2016
46
Association analysis of TOR1A polymorphisms rs2296793 and rs3842225 in a Chinese population with cervical dystonia. ( 26704435 )
2016
47
The role of polymyography in the treatment of cervical dystonia. ( 27314962 )
2016
48
Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. ( 27806874 )
2016
49
Determinants of disability in cervical dystonia. ( 27553512 )
2016
50
Explicit Agency in Patients with Cervical Dystonia: Altered Recognition of Temporal Discrepancies between Motor Actions and Their Feedback. ( 27575487 )
2016

Variations for Cervical Dystonia

Expression for Cervical Dystonia

Search GEO for disease gene expression data for Cervical Dystonia.

Pathways for Cervical Dystonia

Pathways related to Cervical Dystonia according to GeneCards Suite gene sharing:

(show all 18)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.65 GNAL HLA-DQA1 HLA-DQB1 HLA-DRB1
2 12.16 HLA-DQA1 HLA-DQB1 HLA-DRB1
3
Show member pathways
12.08 HLA-DQA1 HLA-DQB1 HLA-DRB1
4 12.03 HLA-DQA1 HLA-DQB1 HLA-DRB1
5
Show member pathways
12 GNAL HLA-DQA1 HLA-DQB1 HLA-DRB1
6
Show member pathways
11.98 HLA-DQA1 HLA-DQB1 HLA-DRB1
7
Show member pathways
11.94 HLA-DQA1 HLA-DQB1 HLA-DRB1
8 11.87 HLA-DQA1 HLA-DQB1 HLA-DRB1
9 11.81 HLA-DQA1 HLA-DQB1 HLA-DRB1
10 11.71 CAMP HLA-DQA1 HLA-DQB1 HLA-DRB1
11
Show member pathways
11.67 HLA-DQA1 HLA-DQB1 HLA-DRB1
12 11.65 HLA-DQA1 HLA-DQB1 HLA-DRB1
13 11.62 HLA-DQA1 HLA-DQB1 HLA-DRB1
14 11.57 HLA-DQA1 HLA-DQB1 HLA-DRB1
15 11.5 HLA-DQA1 HLA-DQB1 HLA-DRB1
16 11.18 HLA-DQA1 HLA-DQB1 HLA-DRB1
17
Show member pathways
11.09 HLA-DQA1 HLA-DQB1 HLA-DRB1
18 10.78 GNAL HLA-DQA1 HLA-DQB1 HLA-DRB1

GO Terms for Cervical Dystonia

Cellular components related to Cervical Dystonia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endosome membrane GO:0010008 9.61 HLA-DQA1 HLA-DQB1 HLA-DRB1
2 trans-Golgi network membrane GO:0032588 9.58 HLA-DQA1 HLA-DQB1 HLA-DRB1
3 endocytic vesicle membrane GO:0030666 9.54 HLA-DQA1 HLA-DQB1 HLA-DRB1
4 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-DQA1 HLA-DQB1 HLA-DRB1
5 transport vesicle membrane GO:0030658 9.43 HLA-DQA1 HLA-DQB1 HLA-DRB1
6 clathrin-coated endocytic vesicle membrane GO:0030669 9.33 HLA-DQA1 HLA-DQB1 HLA-DRB1
7 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-DQA1 HLA-DQB1 HLA-DRB1
8 MHC class II protein complex GO:0042613 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Biological processes related to Cervical Dystonia according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 T cell receptor signaling pathway GO:0050852 9.65 HLA-DQA1 HLA-DQB1 HLA-DRB1
2 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.63 HLA-DQA1 HLA-DQB1 HLA-DRB1
3 T cell costimulation GO:0031295 9.54 HLA-DQA1 HLA-DQB1 HLA-DRB1
4 adenylate cyclase-activating G-protein coupled receptor signaling pathway GO:0007189 9.52 DRD5 GNAL
5 activation of adenylate cyclase activity GO:0007190 9.51 DRD5 GNAL
6 interferon-gamma-mediated signaling pathway GO:0060333 9.5 HLA-DQA1 HLA-DQB1 HLA-DRB1
7 negative regulation of blood pressure GO:0045776 9.49 DRD5 GCH1
8 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.43 DRD5 GNAL
9 regulation of protein localization to cell surface GO:2000008 9.4 BDNF TOR1A
10 antigen processing and presentation GO:0019882 9.33 HLA-DQA1 HLA-DQB1 HLA-DRB1
11 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.26 HLA-DQB1 HLA-DRB1
12 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 8.96 HLA-DQB1 HLA-DRB1
13 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Molecular functions related to Cervical Dystonia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.13 HLA-DQA1 HLA-DQB1 HLA-DRB1
2 MHC class II receptor activity GO:0032395 8.8 HLA-DQA1 HLA-DQB1 HLA-DRB1

Sources for Cervical Dystonia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....